NOTCH1 and breast carcinoma: However, the single silencing of Notch1 could be not sufficient to regain breast cancer cell sensitivity to doxorubicin; therefore, targeting multiple pathways including STAT3 and β-catenin together with Notch1 could provide a more synergistic action with doxorubicin [510,511].